LA
Publicaties op Oncologisch.com
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma...
Neoadjuvant-adjuvant versus adjuvant-only pembrolizumab bij gevorderd melanoom: SWOG S1801 fase II
Adjuvant nivolumab versus ipilimumab bij melanoom: CheckMate 238 vierjaars herbeoordeling
Adjuvant nivolumab versus ipilimumab bij melanoom: CheckMate 238 vierjaars
Neoadjuvante systeemtherapie bij melanoom: internationale consensusaanbevelingen